Florida Cancer Specialists & Research Institute Joins Statewide FLASCO Gathering to Address Current and Future Changes in Cancer Care Delivery

Fort Myers, Fla., October 28, 2022 – Physicians, clinicians and senior leaders of Florida Cancer Specialists & Research Institute, LLC (FCS) will continue their long history of active involvement with the Florida Society of Clinical Oncology (FLASCO) at the FLASCO Fall Session being held in Orlando, Oct. 28 & 29. The gathering of medical oncologists, hematologists, nurse practitioners, pharmacists and other health care professionals who manage and provide care for cancer patients across the state will feature dynamic educational tracks that focus on the latest scientific advancements in cancer care, the effects of novel therapies and barriers to care.

FCS medical oncologist Mohammad Jahanzeb, MD, FACP, FASCO, who provides care to patients at FCS locations in Palm Beach County, will moderate a general session on Lung Cancer Solid Tumor. Kayla Haines, MSN, APRN, FNP-C, an FCS advanced practice provider, will participate as a panelist.

Diane Cope, PhD, APRN, BC, AOCNP, FCS Director of Nursing, will participate as a panelist for “The Expanding Role of the Oncology Nurse.” The session will explore post-COVID patient care, insurance navigation, advance care planning and overcoming barriers to care.

FCS President & Managing Physician Michael Diaz, MD, who served as FLASCO president from 2015 to 2017, said, “FLASCO fosters multidisciplinary collaboration, which is critical in the complex field of oncology. Our active participation in this premier statewide network helps to ensure that we are learning, sharing best practices and finding solutions together with our colleagues from across the state.”

“As a leader in community oncology care and research, we are proud to share our voices and experiences to continuously improve patient outcomes and the overall experience for oncology patients,” said FCS Chief Executive Officer Nathan H. Walcker.

The following FCS medical oncologists currently serve in leadership roles on the FLASCO Board of Directors:

• Maen Hussein, MD – Vice President
• Richard McDonough, MD – Past President and Volunteer Director of Fellows Programs
• Barry Berman, MD, MS – Finance Committee Chair
• Michael Diaz, MD – Past President and Director of Patient Advocacy and Federal Legislative Committee
• Eric Harris, DO – Program Committee Chair
• Faithlore Gardner, MD – Clinical Practice Co-Vice Chair
• Mohammad Jahanzeb, MD, FACP, FASCO – National Comprehensive Cancer Network (NCCN) Liaison
• Scott Tetreault – Legislative State & Federal Vice Chair
• Jennifer Cultrera, MD – Fellowship/President Outreach Program Co-Chair
• William Harrer, MD – FMA Representative

Also serving on the FLASCO Board of Directors are FCS Chief Medical Officer of Therapeutics & Analytics Lucio Gordan, MD and medical oncologists Nalini Hasija, MD, Sachin Kamath, Paresh Patel, MD, Cesar Perez, MD, MD, Magali Van den Bergh, MD and FCS Director of Pharmacy Operations Kristen Boykin, PharmD, BCOP, BCPS.

The Florida Society of Clinical Oncology (FLASCO) is a member-supported statewide non-profit organization committed to facilitating and promoting multidisciplinary efforts for oncology practitioners and industry professionals to improve patient care in Florida.

# # #

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

For More Information, Contact:

Michelle Robey, Vice President of Marketing
Michelle.Robey@FLCancer.com
(813) 767-9398

Jen Bradley, Director of Corporate Communications
Jennifer.Bradley@FLCancer.com
(847) 280-1740